Skip to main content
HYUNDAI BIOSCIENCE CO., LTD. logo

HYUNDAI BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 048410 ISIN · KR7048410005 KO Professional, scientific and technical activities
Open in API
Filings indexed 288 across all filing types
Latest filing 2025-02-06 Major Shareholding Noti…
Country KR South Korea
Listing KO 048410

About HYUNDAI BIOSCIENCE CO., LTD.

http://www.hyundaibioscience.com/eindex…

HYUNDAI BIOSCIENCE CO., LTD. is a biotechnology company focused on developing innovative therapeutics using its proprietary drug delivery system (DDS) technology. The company's core science is based on organic-inorganic hybrid technologies designed to safely and effectively deliver active ingredients. Its main development pipeline includes CP-COV03, a broad-spectrum antiviral agent that enhances cellular autophagy to combat viral infections, and Polytaxel, an anticancer drug candidate developed with polymer transfer technologies to reduce toxicity. The company's primary focus is on creating novel treatments for viral diseases and cancer.

Recent filings

Filing Released Lang Actions
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (Hyundai Bioscience) regarding a 'Collateral Provision Agreement' involving the company's largest shareholder. It details the pledging of shares as collateral for debt financing. This type of disclosure is a standard regulatory requirement for material corporate events involving share ownership and financing, which falls under the 'Regulatory Filings' (RNS) category as it does not fit into specific categories like M&A, Earnings, or Director's Dealing.
2025-02-06 Korean
유상증자또는주식관련사채등의청약결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is an official regulatory filing from Hyundai Bioscience regarding the results of a paid-in capital increase (rights offering). It details the subscription results, including the number of shares subscribed, the subscription rate, and the handling of unsubscribed shares. This falls under the category of capital and financing updates, specifically related to share issuance and capital changes.
2025-02-06 Korean
최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a formal regulatory filing from a Korean company (Hyundai Bioscience) regarding a 'Contract for Stock Collateralization Involving a Change in Largest Shareholder'. This type of disclosure is a standard regulatory requirement in the Korean market (DART system) for reporting significant changes in share ownership or collateral status. Since it does not fit into specific categories like M&A, dividends, or earnings, it falls under the 'Regulatory Filings' (RNS) category as a general corporate disclosure.
2025-02-05 Korean
투자판단관련주요경영사항(임상시험계획승인신청) (뎅기 또는 뎅기 유사 질환 환자를 대상으로 CPCOV03의 베트남 2/3상 임상시험계획 승인 신청서 제출)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Hyundai Bioscience regarding the submission of a clinical trial application (Phase 2/3) for their drug CP-COV03 in Vietnam. It is a formal disclosure of a material management event (major management matter) filed with the Korean stock exchange (KRX). Since it does not fit into specific categories like M&A, dividends, or financial reports, and is a standard regulatory disclosure of a business event, it is classified as a Regulatory Filing (RNS).
2025-02-05 Korean
유상증자최종발행가액확정
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement from Hyundai Bioscience regarding the final determination of the issue price for a paid-in capital increase (rights offering). It details the calculation methodology, the final price per share, and the number of shares to be issued. This falls under the category of capital structure changes and financing activities, specifically related to share issuance.
2025-02-03 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a '주요사항보고서(유상증자결정)' (Major Report: Decision on Paid-in Capital Increase) filed by Hyundai Bioscience. It details the correction of a previously filed capital increase report, specifically updating the final issuance price and related financial figures. This falls under the category of announcements regarding new share issues and capital structure changes, which is classified as 'SHA'.
2025-02-03 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.